Introducing Lecanemab, the Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval

On the latest episode of the podcast, Dementia Matters, host Nathaniel Chin, MD, gives an overview of the new Alzheimer’s treatment Leqembi (lecanemab), and highlights results from thephotograph of Dr. Nathaniel Chin and Dementia Matters logo second and third phases of its clinical trials. On January 6, 2023, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. Listen to the episode on the Wisconsin ADRC website.

Hear more episodes of Dementia Matters on the Wisconsin ADRC website, through ApplePodcasts, Spotify, Podbean or wherever you get your podcasts.